193 completed, 76 recruiting, 52 terminated, 33 active not recruiting. 408 Phase 1, 137 Phase 2.
Follow Neoplasms, Connective Tissue: new trials by email Literature Review of Neoplasms, Connective Tissue trials Research Report on Neoplasms, Connective Tissue
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| GD2IL18CART Combined With Bevacizumab for Relapsed and Refractory GD2-positive Solid Tumors Chimeric Antigen Receptor (CAR) Therapy Infusion, Bevacizumab (Avastin) - Neuroblastoma (NBL), Ewing Sarcoma | Phase 1 | Not yet recruiting | Universität Münster | 30 | 2027-10-01 | 2026-11-03 |
| Combination Immunotherapy Targeting Sarcomas Multiple sarcoma-specific CAR-T cells and sarcoma vaccines - Sarcoma, Osteoid Sarcoma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 20 | 2027-07-01 | 2026-11-02 |
| Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas Sarcoma-specific CAR-T cells - Sarcoma, Osteoid Sarcoma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 20 | 2027-06-01 | 2026-10-30 |
| SPARK UPS/MFS: Study Of BET Inhibition With ZEN003694 To Potentiate Anti-Tumor Responses With Radiotherapy To Kickstart Abscopal Effect In Metastatic Undifferentiated Pleomorphic Sarcoma (UPS) And Myxofibrosarcoma (MFS). ZEN003694, Radiation Therapy - Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma | Phase 1 / Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 57 | 2027-05-31 | 2026-11-18 |
| A Phase 1/2 Study of CBX-12 in Children, Adolescents, or Young Adults With Solid Tumors That Have Come Back After Treatment or Are Difficult to Treat Archive Sample Retrieval, Biospecimen Collection, pH Low Insertion Peptide-exatecan Conjugate CBX-12 - Recurrent Childhood Ewing Sarcoma, Recurrent Childhood Malignant Solid Neoplasm | Phase 1 / Phase 2 | Not yet recruiting | Children's Oncology Group | 79 | 2027-05-07 | 2026-09-22 |
| A Safety Study of ST316 in Participants With Familial Adenomatous Polyposis (FAP). ST316 IV - Familial Adenomatous Polyposis (FAP) | Phase 1 | Not yet recruiting | Sapience Therapeutics | 40 | 2027-01-04 | 2026-08-12 |
| Mercaptopurine for the Treatment of Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC), Uterine/Cutaneous Leiomyomas, and Kidney Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Kidney Carcinoma, Advanced Renal Cell Carcinoma | Phase 1 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 18 | 2026-12-01 | 2026-08-06 |
| EWSR1 Immunotherapy in Ewing Sarcoma and DSRCT EWSR1 immunotherapy, Pembrolizumab - Ewing Sarcoma, Desmoplastic Small Round Cell Tumor | Phase 1 | Not yet recruiting | Rabi Hanna | 24 | 2026-10-01 | 2026-09-17 |
| Phase I/II Trial of Dinutuximab Beta in Combination With Irinotecan and Rapamycin in Pediatric, Adolescents and Adult Patients With Relapsed/Refractory Bone Tumors. Dinutuximab beta, Sirolimus and Irinotecan - Osteosarcomas, Bone Cancer | Phase 1 / Phase 2 | Not yet recruiting | University Hospital, Strasbourg, France | 89 | 2026-10-01 | 2026-10-01 |
| Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma Surgical Resection, Stereotactic Body Radiation Therapy (SBRT), Atezolizumab - Osteosarcoma, Pulmonary Recurrence of Osteosarcoma | Phase 1 | Recruiting | Emory University | 12 | 2026-10-01 | 2026-09-30 |
| A Study to Assess Safety and Efficacy of SOT106 in Patients With LRRC15-positive Advanced Unresectable or Metastatic Osteosarcoma or Soft Tissue Sarcoma SOT106 - Osteosarcoma Metastatic, Soft Tissue Sarcoma (STS) | Phase 1 / Phase 2 | Not yet recruiting | SOTIO Biotech a.s. | 70 | 2026-09-30 | 2026-09-03 |
| TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors TLN-499, Venetoclax - Small Cell Lung Cancer ( SCLC ), Neuroendocrine Cancer | Phase 1 | Recruiting | Treeline Biosciences, Inc. | 120 | 2026-08-05 | 2026-10-01 |
| Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor BMS-986504 - Malignant Peripheral Nerve Sheath Tumors, MPNST | Phase 1 / Phase 2 | Recruiting | Ankit Mangla, MD | 17 | 2026-08-01 | 2026-08-11 |
| Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and Osteosarcoma Domatinostat, Sirolimus - Sarcoma, Osteosarcoma | Phase 1 / Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 74 | 2026-07-15 | 2026-09-03 |
| NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma i15.NKG2D.zeta NK cells and C7R.GD2.CARTs cells - Relapsed Neuroblastoma, Refractory Neuroblastoma | Phase 1 | Recruiting | Baylor College of Medicine | 27 | 2026-07-15 | 2026-07-21 |
| Study of DCC-2618 in Patients With GIST After at Least 3 Prior Treatments DCC-2618 - Gastrointestinal Stromal Tumors | Phase 1 | Recruiting | Ono Pharmaceutical Co., Ltd. | 10 | 2026-07-07 | 2026-07-20 |
| Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST APG-115, Selumetinib - Malignant Peripheral Nerve Sheath Tumor (MPNST), Neurofibromatosis 1 (NF1) | Phase 1 / Phase 2 | Recruiting | AeRang Kim | 45 | 2026-06-01 | 2026-07-27 |
| Preoperative Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor Imatinib, Fampridine - Gastrointestinal Stromal Tumors | Phase 1 | Recruiting | University of California, San Diego | 18 | 2026-05-13 | 2026-05-27 |
| Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas Eflornithine (DFMO), AMXT 1501 Dicaprate - Atypical Teratoid/Rhabdoid Tumor, Embryonal Tumor With Multilayered Rosettes | Phase 1 / Phase 2 | Recruiting | Milton S. Hershey Medical Center | 265 | 2026-05-13 | 2026-09-03 |
| A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies ZI-MA4-1 (TCR-NK cells), Cyclophosphamide, Fludarabine - Ovarian Cancer, Squamous Non-Small Cell Lung Cancer (NSCLC) | Phase 1 | Recruiting | Zelluna Immunotherapy AS | 9 | 2026-05-11 | 2026-09-04 |
Showing 20 of 408. Sign in to see all of them.
Osteosarcoma (150) · Sarcoma (141) · Sarcoma, Ewing (105) · Neuroblastoma (86) · Rhabdomyosarcoma (66) · Gastrointestinal Stromal Tumors (63) · Sarcoma, Synovial (58) · Melanoma (50) · Ovarian Neoplasms (50) · Neoplasms (45) · Wilms Tumor (41) · Neurofibrosarcoma (35) · Carcinoma, Non-Small-Cell Lung (33) · Breast Neoplasms (32) · Carcinoma, Hepatocellular (30)
Neoplasms by Histologic Type (407) · Neoplasms, Connective and Soft Tissue (405) · Neoplasms (363) · Neoplasms, Bone Tissue (212) · Neoplasms by Site (188) · Neoplasms, Glandular and Epithelial (181) · Neoplasms, Nerve Tissue (169) · Sarcoma (165) · Neuroectodermal Tumors (141) · Neoplasms, Germ Cell and Embryonal (134) · Digestive System Diseases (120) · Urogenital Diseases (119) · Digestive System Neoplasms (118) · Urogenital Neoplasms (116)
Cyclophosphamide (33) · Imatinib Mesylate (19) · Irinotecan (19) · Carboplatin (15) · Temozolomide (15) · fludarabine (14) · Gemcitabine (13) · Doxorubicin (12) · Filgrastim (12) · Leucovorin (12) · Cisplatin (11) · Ifosfamide (11) · Paclitaxel (11) · Bevacizumab (10) · Etoposide (9)
National Cancer Institute (NCI) (45) · M.D. Anderson Cancer Center (11) · Memorial Sloan Kettering Cancer Center (9) · St. Jude Children's Research Hospital (9) · Gynecologic Oncology Group (8) · Emory University (7) · Children's Oncology Group (6) · Deciphera Pharmaceuticals, LLC (6) · Fred Hutchinson Cancer Center (6) · Novartis Pharmaceuticals (6) · City of Hope Medical Center (5) · Dana-Farber Cancer Institute (5) · Eli Lilly and Company (5) · Mayo Clinic (5) · Peking University People's Hospital (5)
United States (314) · France (43) · Spain (34) · China (32) · Italy (31) · United Kingdom (31) · Germany (28) · Canada (27) · Australia (26) · Netherlands (19) · Japan (18) · South Korea (18) · Belgium (13) · Denmark (11) · Poland (10)
AeRang Kim, MD, PhD (4) · Holly Meany, MD (3) · Jonathan Metts, MD (3) · Matteo Trucco, MD (3) · Peter G. Rose, MD (3) · Thomas Cash, MD, MSc (3) · Brigitte C Widemann, M.D. (2) · Catherine Albert, MD (2) · Crystal L Mackall, M.D. (2) · Don Dizon (2)
PMID 31401903, PMID 32192573, PMID 11705489, PMID 12528778, PMID 12957454, PMID 15010069, PMID 15592836, PMID 15814645, PMID 16234526, PMID 16412499, PMID 16551859, PMID 16631245, PMID 16775235, PMID 16914576, PMID 16959305, PMID 17715389, PMID 18048828, PMID 18281544, PMID 18391430, PMID 18470481, PMID 19075272, PMID 19088049, PMID 19430790, PMID 19671873, PMID 20036194, PMID 20044751, PMID 20226028, PMID 20407240, PMID 20460632, PMID 20622000, PMID 21098399, PMID 22186789, PMID 22626269, PMID 22682017, PMID 22847809, PMID 23071222, PMID 23255417, PMID 23382028, PMID 23547655, PMID 23664013, PMID 24057647, PMID 24060561, PMID 24089446, PMID 24711551, PMID 24739759, PMID 25452614, PMID 25634727, PMID 25858498, PMID 25917459, PMID 26002753
U10CA027469 (8), 2023 (6), 2015 (5), U01CA069856 (5), UM1CA228823 (5), P30CA008748 (4), P30CA033572 (4), P30CA015704 (3), U01CA097452 (3), 2018 (2), 2019 (2), P30CA015083 (2), P30CA016087 (2), P30CA068485 (2), P50CA136393 (2)